Move to topTop
January 21, 2017

TOKYO, JAPAN - Jan. 21, 2017 - Terumo Corporation (TSE: 4543) announced today that it has completed its acquisition of certain assets owned by Abbott and St. Jude Medical on Jan. 20, 2017 (North American Central Standard Time). Terumo has acquired the Angio-Seal™ and FemoSeal™ vascular closure product lines and Kalila Medical, Inc., a company developing next-generation access technologies, the first being the Vado™ Steerable Sheath, used in cardiac electrophysiology procedures.

The acquired assets become part of Terumo Interventional Systems, a division of Terumo Corporation. By building on Terumo's existing infrastructure and competencies, the acquisition will enable Terumo to maximize the value of the acquired businesses and contribute to supporting safe and efficient interventional procedures.

The financial impact will be included on a consolidated basis, starting with the fourth quarter of the fiscal year ending March 31, 2017. The impact of the acquisition on Terumo's business performance is being examined. Further details regarding the impact of the acquisition will be disclosed as needed, once the analysis is completed.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.